The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Commentary|Articles|August 5, 2026
- Vol.27/No.9
- Volume 27
- Issue 09
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Road Map
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Nicole Canfora Lupo
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Advertisement
Advertisement
Antibody-drug conjugates (ADCs) are diversifying the first- and subsequent-line breast cancer treatment arenas, but despite recent FDA approvals providing earlier access to these highly effective treatments, questions remain regarding appropriate decision-making in the second-line setting and beyond.
Related to this article
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement